Skip to content
Pharmeasy logo
Pre-IPOPublic Limited

Pharmeasy Unlisted Share Price

API Holdings Ltd - Pharmeasy

Consumer·E-commerce

CIN
U60100MH2019PLC323444
ISIN
INE0DJ201029
Incorporated
31 Mar 2019
Registered state
Maharashtra

Key valuation

Market cap
₹9,538 Cr
P/E
—
Debt / equity
0.6x
Shares outstanding
17,03,21,42,857

Indicative price

₹5.60prev ₹5.60

1M

-25.33%

6M

-10.40%

1Yr

-19.42%

Max

-62.67%

Updated 17 Nov 2026, 08:10

Prices shown are indicative, dealer-quoted and updated periodically — they are not exchange-traded prices and may differ from the price at which a transaction is finally executed.

Price history

Dated dealer-quote averages, plotted on a true time scale. There is no continuous trading behind these numbers.

-19.42%since 17 Nov 2025High ₹9.95Low ₹5.60314 dated snapshots

About Pharmeasy

API Holdings Limited is the parent company of PharmEasy, one of India's largest online pharmacy and healthcare platforms. It was incorporated in 2019 and is based in Mumbai.

Through about 26 subsidiaries, the group runs consumer medicine delivery, pharmaceutical distribution to retailers, diagnostics and teleconsultation. Customers order prescription medicines, OTC and wellness products on PharmEasy, while subsidiaries such as Thyrocare provide diagnostic testing. Much of the group's growth came through acquisitions, including Thyrocare and Docon.

API Holdings remains loss-making but is narrowing its losses: it reported revenue of ₹5,872 crore and a net loss of ₹1,572 crore in FY2025, compared with ₹5,664 crore and a ₹2,534 crore loss in FY2024.

Key highlights

  • Incorporated in 2019

Financial snapshot

FY2025

Revenue FY2025
₹5,872.16 Cr
EBITDA
₹-841.80 Cr
PAT
₹-1,572.39 Cr
Net worth
₹3,272.28 Cr
Total debt
₹2,034.00 Cr
Cash & equivalents
₹118.99 Cr
Operating cash flow
₹-223.53 Cr
EPS
₹-0.92

Management & board

  • AP

    Aditya Puri

    Director

    Since 2021
  • RR

    Ravi Rajagopal

    Additional Director

    Since 2026
  • DC

    Deepak Calian Vaidya

    Director

    Since 2021
  • AK

    Alok Kumar Jagnani

    CFO, Whole-time director

    Since 2025
  • RR

    Ranjan Ramdas Pai

    Director

    Since 2024
  • SS

    Subramaniam Somasundaram

    Director

    Since 2021
  • SP

    Shyam Powar

    Director

    Since 2024
  • JD

    Jaydeep Dahyalal Tank

    Director

    Since 2021
  • SB

    Siddharth Bhaskar Shah

    Director

    Since 2020
  • VR

    Vineeta Rai

    Director

    Since 2021
  • AS

    Ashutosh Sharma

    Director

    Since 2021
  • NR

    Namita Rungta

    Individual Promoter

    Since 2019
  • NR

    Nimesh Rungta

    Individual Promoter

    Since 2019
  • RF

    Rahul Franklin Guha

    CEO, Managing Director

    Since 2025

Reported financials · FY2021–FY2025

Figures in ₹ crore unless stated.

Revenue CAGR 25.9%
ParticularsFY2021FY2022FY2023FY2024FY2025YoYCAGR
Profit & loss
Revenue from operationsYoY +3.7%CAGR +25.9%2,3355,7296,6445,6645,872+3.7%+25.9%
Other incomeYoY +13.9%CAGR +43.6%25525695108+13.9%+43.6%
Total expensesYoY -0.6%CAGR +25.5%2,9058,4928,9747,2557,209-0.6%+25.5%
EBITDA-569-2,294-4,288-1,578-842——
Depreciation & amortisationYoY -21.8%CAGR +50.5%33159243216169-21.8%+50.5%
EBIT-602-2,452-4,531-1,794-1,011——
Finance costYoY -30.5%CAGR +84.8%43258666728506-30.5%+84.8%
Profit before tax-620-3,971-5,197-2,522-1,517——
Tax expenseYoY +382.6%CAGR +27.4%2122151256+382.6%+27.4%
Profit after tax-641-3,993-5,212-2,534-1,572——
Earnings per share₹-0.38₹-2.34₹-3.06₹-1.49₹-0.92——
Balance sheet
Net worthYoY +26.4%CAGR -2.2%3,5817,0222,4372,5883,272+26.4%-2.2%
Total debtYoY -50.4%CAGR +342.4%52,5854,1204,0982,034-50.4%+342.4%
Current liabilitiesYoY -49.1%CAGR +100.1%1113,7622,3233,5021,781-49.1%+100.1%
Cash & equivalentsYoY -63.7%CAGR -15.2%230157194328119-63.7%-15.2%
Current assetsYoY -27.7%CAGR +9.7%1,7362,5022,5353,4762,513-27.7%+9.7%
Total assetsYoY -16.8%CAGR +9.2%4,90511,3988,2568,3906,977-16.8%+9.2%
Cash flow
Operating activities-179-2,589-744-61-224——
Investing activities-954-5,789-72-1,261775——
Financing activitiesYoY -152.2%CAGR —1,1198,3058531,457-760-152.2%—
Free cash flow-1842,446-839-133-304——
Net change in cashYoY -254.7%CAGR —-15-7337135-208-254.7%—

YoY compares the latest year with the one before it. CAGR runs from the oldest reported year to the latest. A dash means the year is missing, or the starting figure is zero or negative, so a percentage would mislead.

Margins, returns, liquidity, leverage and every other ratio from these figures: see Ratios

Revenue, EBITDA and PAT

₹ crore. A year with no reported figure is left out rather than drawn as zero.

-5,212-2,2487163,6806,644FY2021 · Revenue: 2,335FY2021 · EBITDA: -569FY2021 · PAT: -641FY2021FY2022 · Revenue: 5,729FY2022 · EBITDA: -2,294FY2022 · PAT: -3,992FY2022FY2023 · Revenue: 6,644FY2023 · EBITDA: -4,288FY2023 · PAT: -5,212FY2023FY2024 · Revenue: 5,664FY2024 · EBITDA: -1,578FY2024 · PAT: -2,534FY2024FY2025 · Revenue: 5,872FY2025 · EBITDA: -842FY2025 · PAT: -1,572FY2025
-5,212-2,2487163,6806,644FY2021 · Revenue: 2,335FY2021 · EBITDA: -569FY2021 · PAT: -641FY2021FY2022 · Revenue: 5,729FY2022 · EBITDA: -2,294FY2022 · PAT: -3,992FY2022FY2023 · Revenue: 6,644FY2023 · EBITDA: -4,288FY2023 · PAT: -5,212FY2023FY2024 · Revenue: 5,664FY2024 · EBITDA: -1,578FY2024 · PAT: -2,534FY2024FY2025 · Revenue: 5,872FY2025 · EBITDA: -842FY2025 · PAT: -1,572FY2025
  • Revenue
  • EBITDA
  • PAT

Every ratio here is worked out from the reported figures in the Financials tab, and valuation multiples from the indicative price in the header. Nothing is a stored value. A ratio the filings cannot support (a line not reported, or a zero or negative base) is left out or shown as —, never as a misleading number. Balance-sheet ratios use year-end figures.

Valuation multiples

What the indicative price pays for the latest year's earnings, book and cash. On FY2025 figures and the ₹5.60 indicative price.

Market cap
₹9,538 Cr
Enterprise value
₹11,453 Cr
Price / book (P/B)
2.91x
Price / sales (P/S)
1.62x
EV / sales
1.95x
Earnings yield
-16.5%
Free cash flow yield
-3.2%
Cash / market cap
1.3%
How these are worked out
Market cap
Indicative price × shares outstanding
Enterprise value
Market cap + debt − cash
Price / book (P/B)
Market cap ÷ net worth
Price / sales (P/S)
Market cap ÷ revenue from operations
EV / sales
Enterprise value ÷ revenue from operations
Earnings yield
PAT ÷ market cap
Free cash flow yield
(Operating cash flow − capex) ÷ market cap
Cash / market cap
Cash & equivalents ÷ market cap

Shareholding pattern

Latest disclosed. The source does not state a date.

Largest holder: Naspers Ventures BV 13.24%

13.2%11.9%55.0%

IPO / listing status

Pre-IPONot yet announced

The company has not announced IPO details such as a DRHP filing, an expected window or its bankers. This section will update once it does.

Research & news

Research, articles and news on Pharmeasy, newest first. Open any item to read it.

Documents

Private documents are shown locked and are released to verified clients on request.

DocumentTypeFY / dateAccess
Annual Report FY 2025-26Annual report · FY 2025-26 · 4.2 MB4.2 MBAnnual reportFY 2025-26ViewDownload
Annual Report FY 2023-24Annual report · FY 2023-24 · 2.4 MB2.4 MBAnnual reportFY 2023-24ViewDownload
Annual Report FY 2022-23Annual report · FY 2022-23 · 1.1 MB1.1 MBAnnual reportFY 2022-23ViewDownload

Pharmeasy unlisted shares: FAQs

What is the Pharmeasy unlisted share price today?

The indicative price of API Holdings Ltd - Pharmeasy shares is ₹5.60 per share, as of 17 Nov 2026. Unlisted shares have no exchange price: this figure reflects recent off-market deals and can differ from the price on a particular trade. The price history on this page shows how it has moved.

How can I buy Pharmeasy unlisted shares?

Raise a buy enquiry on this page with the number of shares you want. Our desk confirms availability and the price, you pay from a bank account in your own name, and the shares are transferred to your demat account. You need a PAN and a demat account with any depository participant.

How can I sell Pharmeasy shares?

Raise a sell enquiry with the number of shares you hold in demat. Once the price is agreed, you transfer the shares from your demat account and the money is paid to a bank account in your name.

Is Pharmeasy planning an IPO?

API Holdings Ltd - Pharmeasy is currently at the "Pre-IPO" stage. No IPO date has been announced. A listing depends on the company and on regulatory approval.

What are Pharmeasy's revenue and profit?

In FY25, API Holdings Ltd - Pharmeasy reported revenue of ₹5,872 Cr and a loss of ₹1,572 Cr, with a net worth of ₹3,272 Cr. The Financials section has the full statements for every year we hold.

Is it legal to buy unlisted shares in India?

Yes. Shares of unlisted public companies can be bought and sold off-market and transferred between demat accounts. They carry more risk than listed shares: prices are not set on an exchange, it can take time to find a buyer, and a listing is never guaranteed.

Is there a lock-in on Pharmeasy shares after the IPO?

SEBI rules lock in shares held before an IPO for a period after listing, currently six months from allotment for most investors in a mainboard IPO. Shares bought now in the unlisted market would usually be covered by this lock-in.

How are gains on Pharmeasy unlisted shares taxed?

Gains on unlisted shares held for more than 24 months are long-term capital gains; held for less, they are short-term and taxed at your slab rate. Check the current rates with a tax adviser before you sell.